News

AbbVie targets psychedelic-based depression drug market with $1.2 billion deal

AbbVie will buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion, the companies ...

Metformin: Science finds new benefits from an old drug

A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...

FDA approves use of animal drugs to treat New World Screwworm

The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New ...
STAT2d

FDA says it will publish reports of adverse events tied to drugs on daily basis

The FDA said it has begun publishing reports of adverse events concerning drugs on a daily basis, instead of quarterly, as it ...
BioPharma Dive17d

FDA to start new ‘precheck’ program to boost US drug production

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

Indole chemistry advance could accelerate drug development with precise targeting

Indole, a molecule made up of a six-membered benzene ring fused to a five-membered ring containing nitrogen, forms the core ...

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

People’s Pharmacy: Is there a way to petition the FDA to change a drug’s classification?

A. The Food and Drug Administration has approved montelukast to treat asthma, exercise-induced bronchoconstriction (trouble ...

FDA’s new expert panels are rife with financial conflicts and fringe views

A series of panels convened by the Food and Drug Administration is raising concerns that the agency is skirting federal rules ...

Texas, Florida ask to join mifepristone case, boosting effort to ban abortion drug

Texas and Florida, which have near-total abortion bans, said nationwide access to mifepristone makes it impossible for the ...
The Manila Times3h

Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4

The Rare Pediatric Disease Designation may allow Arnatar to receive a Priority Review Voucher (PRV) upon ART4’s potential marketing approval, which could be used to expedite the review of another drug ...